GSK3B and endometrial cancer: Moreover, the GSK3β inhibitor LY2090314 – which has already undergone clinical testing [30]– induced ETS1 degradation in ovarian and endometrial cancer cells (Figure 3D), an effect blocked by MG132 in the presence of GSK3β siRNA (Figure 3E).